Stable CAD (Coronary artery disease)

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

This study aimed at comparing the effects of fractional flow reserve- vs. optical coherence tomography-guided treatment of angiographically intermediate coronary stenosis.

Thank you to the thousands of cardiologists and healthcare professionals whose contribution to the website provides the community with a valuable, free resource of education in cardiovascular interventions - this embodies the By and For that sets PCRonline apart! Thanks to you, over half a million...

Consult this session to learn more about the role of FFR in stable coronary artery disease intervention, the common pitfalls and tips & tricks in performing FFR measurement, as well as the emerging role of QFR in assessing the significance of intermediate stenosis.

Concomitant coronary artery disease (CAD) is frequently found in patients with severe aortic stenosis (AS) undergoing treatment with transcatheter aortic valve implantation (TAVI).

CorMicA was a randomised control trial comparing medical therapy guided by invasive coronary function testing (CFR, IMR and acetylcholine provocation) versus standard care in 151 patients with symptoms and/or signs of ischaemia with no obstructive coronary artery disease (INOCA).

One of the most discussed limitations of GLOBAL-LEADER is the lack of event adjudication so that the rate of MI, bleeding or stent thrombosis between the two groups were unknown. In this study, events were adjudicated in those patients from the 20 top-enrolling participating sites.

Over the past year, an abundance of clinical evidence has emerged addressing the conceptually appealing and theoretically justified concept of dropping aspirin, rather than the P2Y12 antagonist, as part of antiplatelet regimens after percutaneous coronary intervention (PCI).

Editors M. Sabaté and S. Brugaletta share how the additional live cases, videos and media content provide crystal clear tips and tricks on new procedures.

The TWILIGHT trial was designed to test the hypothesis that in patients undergoing PCI who are at high risk for ischemic or hemorrhagic complications and who have completed a 3-month course of DAPT with ticagrelor plus aspirin, continued treatment with ticagrelor monotherapy would be superior to ticagrelor...